Table 1.
Phase IIb and III HIV vaccine efficacy trials.
| Vaccine trial | Vaccine candidate and immunogens | Specimens collected |
Most significant immune response elicited | Reference | |
|---|---|---|---|---|---|
| Systemic | Mucosal | ||||
| HVTN 502/Merck 023 STEP Study (Phase IIb/prophylactic) | MRKAd5 HIV-1 gag/pol/nef | Serum, plasma, PBMCs | Not collected | T cell response | Buchbinder et al. (47) |
| HVTN 503 Phambili Study (Phase IIb/prophylactic) | MRKAd5 HIV-1 gag/pol/nef | Serum, plasma, PBMCs | Not collected | T cell response | Gray et al. (48) |
| HVTN 505 (Phase IIb/prophylactic) | VRC-HIVDNA016-00-VP/VRC-HIVADV014-00-VP | Serum, plasma, PBMCs | Not collected | T cell and antibody responses (gp140 binding IgG) | Hammer et al. (49) |
| RV144 (Phase III/prophylactic) | ALVAC-HIV vCP1521/AIDSVAX-gp120 B/E | Serum, plasma, PBMCs | Collected but inadequate | T cell and antibody responses (non-neutralizing antibodies to the V1/V2 loop) | Rerks-Ngarm et al. (50) |
| VAX 003 (Phase III/prophylactic) | AIDSVAX B/E (gp120) | Serum, plasma, PBMCs | Not collected | Antibody response (binding and neutralizing antibodies to gp120) | Pitisuttithum et al. (51) |
| VAX 004 (Phase III/prophylactic) | AIDSVAX B/B (gp120) | Serum, plasma, PBMCs | Not collected | Antibody response (binding and neutralizing antibodies to gp120) | Flynn et al. (52), Gilbert et al. (53) |
PBMCs, peripheral blood mononuclear cells.